Jazz hands Zymeworks a much-needed win for biliary tract cancer drug after peek at data

Zymeworks executives didn’t want to speak for Jazz Pharmaceuticals about the strength of data from a midstage readout for biliary tract cancer drug zanidatamab earlier this week. But it didn’t take long for Jazz to speak up loud and clear: We’re in.